TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06634888

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Injectable platelet rich fbirin
Description: After the leveling and alignment phase, the canines were retracted with 150gm forces. The i-PRF was prepared from the blood of each patient then injected immediately before canine retraction on the buccal and palatal aspects of the extraction sites. All patients in this study were submitted for Cone beam computed tomography (CBCT) scanning before and after canine retraction. Cone beam computed tomography (CBCT) was used before and four months after retraction, with imaging conducted using the Orthophos SL 3D X-ray machine (Dentsply Sirona, Charlotte, CA, USA) while adhering to As Low As Reasonably Achievable (ALARA) guidelines to minimize radiation exposure

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Injectable platelet rich fbirin
Description: All patients in this study were submitted for Cone beam computed tomography (CBCT) scanning before and after canine retraction. Cone beam computed tomography (CBCT) was used before and four months after retraction, with imaging conducted using the Orthophos SL 3D X-ray machine (Dentsply Sirona, Charlotte, CA, USA) while adhering to As Low As Reasonably Achievable (ALARA) guidelines to minimize radiation exposure
Study: NCT05584215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for Psychosis Groups
Description: Groups based on cognitive behavioural therapy for psychosis
Study: NCT05542355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXL01
Description: Oral EXL01 once daily for up to 24 weeks (after SoC corticosteroid induction therapy).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXL01
Description: Oral EXL01 once daily for up to 24 weeks (after SoC corticosteroid induction therapy).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral EXL01 matching placebo once daily for up to 24 weeks (after SoC corticosteroid induction therapy).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SoC corticosteroid - Induction Period
Description: Oral prednisone 40 mg or budesonide 9 mg once daily for 3 to 7 weeks, as assigned by the investigator

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SoC corticosteroid - Induction Period
Description: Oral prednisone 40 mg or budesonide 9 mg once daily for 3 to 7 weeks, as assigned by the investigator

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SoC corticosteroid - Induction Period
Description: Oral prednisone 40 mg or budesonide 9 mg once daily for 3 to 7 weeks, as assigned by the investigator

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SoC corticosteroid - Tapering
Description: Same product as the Induction Period.~Oral prednisone: 30 mg for 1 week, 25 mg for 1 week, 20 mg for 1 week, 15 mg for 1 week, 10 mg for 1 week, 5 mg for 1 week and stop.~OR~Oral budesonide: 6 mg for 3 weeks, 3 mg for 3 weeks, stop.
Study: NCT04340947

Intervention type: OTHER
Group type: OTHER
Intervention: Very low nicotine cigarettes
Description: Participants will be randomized to smoke menthol and non-menthol flavored very low nicotine cigarettes in their home environment for 7 days and in the laboratory

Intervention type: OTHER
Group type: OTHER
Intervention: Very low nicotine cigarettes
Description: Participants will be randomized to smoke menthol and non-menthol flavored very low nicotine cigarettes in their home environment for 7 days and in the laboratory
Study: NCT04744194

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nordic hamstring exercise program
Description: Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 - 3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assisted nordic hamstring exercise program
Description: Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 - 3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps.
Study: NCT05925647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Messenchymal stem cell secretome
Description: Mesenchymal stem cell secretome obtained from Kalbe Pharma Company

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl 0,9% infusion
Study: NCT06538272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2910
Description: ONO-2910 Tablet will be orally administered once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Tablet will be orally administered once daily.
Study: NCT06537167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation
Description: Participants will receive proper transcutaneous electrical acupoint stimulation treatment for three consecutive days. Each day, the selected five target acupoints (Renying, Quchi, Taichong, Zusanli, and Hegu) will be stimulated in rotation. Each acupoint will be stimulated once a day for 10 minutes, with a 2-minute interval between each acupoint, totaling 60 minutes. Throughout the trial, the stimulation parameters for each participant will remain constant, and the treatment will begin between 8:00 and 10:00 AM each day.
Study: NCT05542355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SoC corticosteroid - Tapering
Description: Same product as the Induction Period.~Oral prednisone: 30 mg for 1 week, 25 mg for 1 week, 20 mg for 1 week, 15 mg for 1 week, 10 mg for 1 week, 5 mg for 1 week and stop.~OR~Oral budesonide: 6 mg for 3 weeks, 3 mg for 3 weeks, stop.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SoC corticosteroid - Tapering
Description: Same product as the Induction Period.~Oral prednisone: 30 mg for 1 week, 25 mg for 1 week, 20 mg for 1 week, 15 mg for 1 week, 10 mg for 1 week, 5 mg for 1 week and stop.~OR~Oral budesonide: 6 mg for 3 weeks, 3 mg for 3 weeks, stop.
Study: NCT06635408

Intervention type: DIAGNOSTIC_TEST
Intervention: cystatin c
Description: a biomarker to assess renal function

Intervention type: DIAGNOSTIC_TEST
Intervention: cystatin c
Description: a biomarker to assess renal function
Study: NCT06457750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feeding, Lifestyle, Activity Goals (FLAGs) Digital Health Application
Description: Feeding, lifestyle, activity goals (FLAGs) is a digital assessment and advisory tool developed by the investigators to facilitate early identification of lifestyle behaviour problems and abnormal feeding patterns in infants, with real-time feedback for caregivers. The FLAGs questionnaire examines the domains of energy regulation, timeliness and adequacy of weaning, dietary practices, and lifestyle habits. Tailored recommendations have been developed for each domain accordingly. The objective of FLAGs is shaping healthy lifestyle and feeding behaviours from birth, charting a trajectory to optimal metabolic health.
Study: NCT04639414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector
Description: Measurement of the effect of the combined treatment with semaglutide 1mg/week and empagliflozin 10 mg/d compared to matching placebo after 48-week treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide
Description: Measurement of the effect of empagliflozin monotherapy 10mg/d compared to matching placebo after 48-week treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching empagliflozin and placebo pen injector matching semaglutide
Description: Measurement of the effect of the combined treatment with semaglutide 1mg/week and empagliflozin 10 mg/d OR empagliflozin monotherapy 10mg/d compared to matching placebo after 48-week treatment.
Study: NCT05954143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDC-1001
Description: BDC-1001 is an immune-stimulating antibody conjugate (ISAC) designed to be delivered systemically (intravenously) and act locally by targeting HER2-expressing tumors and related metastatic disease for destruction by the innate and adaptive immune systems. BDC-1001 consists of an investigational biosimilar of the humanized monoclonal antibody (mAb) trastuzumab that is chemically conjugated to a toll-like receptor (TLR)7/8 agonist (payload) with an intervening non-cleavable, cell membrane impermeable linker.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDC-1001
Description: BDC-1001 is an immune-stimulating antibody conjugate (ISAC) designed to be delivered systemically (intravenously) and act locally by targeting HER2-expressing tumors and related metastatic disease for destruction by the innate and adaptive immune systems. BDC-1001 consists of an investigational biosimilar of the humanized monoclonal antibody (mAb) trastuzumab that is chemically conjugated to a toll-like receptor (TLR)7/8 agonist (payload) with an intervening non-cleavable, cell membrane impermeable linker.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab is a monoclonal antibody that targets HER2 and prevents dimerization of HER2 with other members of the HER family (HER1, HER3, and HER4), thereby blocking ligand-activated downstream signaling.
Study: NCT05741125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DSME + ASE intervention (Centering Appetite)
Description: The intervention will enable participants to relearn their stomach's hunger and fullness signals and monitor their appetite. Participants will also learn strategies for glucose monitoring and carbohydrate management. Monthly booster sessions will be devoted to problem-solving, addressing barriers to emotion management, and self-monitoring type 2 diabetes mellitus symptoms. Participants will also receive weekly lessons with interactive activities delivered via a digital app.
Study: NCT06422741

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: grape seed proanthocyanidin extract
Description: 250 mg of product presented in capsule form will be given.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 165 mg of cellulose will be given presented in capsule form.
Study: NCT05627128

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DAIN
Description: Participants in the experimental arm will have access to the newly created DAIN curriculum including menus, recipes, and recorded 'how to' recipes. Participants in the experimental arm will also have once-per-week dietary counseling with DAIN-trained nutritionists and monthly cooking classes with a DAIN-trained chef.
Study: NCT06635083

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation
Description: A video conference software system will be installed on the subjects' laptops or tablets. Then, via video conference, strengthening/stretching exercises and breathing exercises will be performed for the areas affected by the deformity with the physiotherapist three times a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: A video conference software system will be installed on the subjects' laptops or tablets. Then, via video conference, strengthening/stretching exercises and breathing exercises will be performed for the areas affected by the deformity with the physiotherapist three times a week.
Study: NCT06635733

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rhapsode Capable™ Platform (Intervention Group)
Description: Participants in the intervention group will use the Rhapsode Capable™ platform to facilitate In-Person Skills Practice (ISP) sessions. The platform allows for scheduling ISP sessions, providing real-time performance feedback, and tracking progress. The platform integrates with the PACE adaptive learning modules, which cover pediatric acute care topics. The goal is to improve skills retention and performance in pediatric care through a blended learning approach.
Study: NCT05200299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOXIRI
Description: mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150-165 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400-2800mg/m2 as a 46-48 hour continuous infusion on day 1)
Study: NCT06537167

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Participants will receive sham stimulation treatment, where the left-side skin near the selected five target acupoints (avoiding other functional acupoints) will be stimulated in rotation. The stimulation time and method will be the same as in the experimental group. Throughout the trial, the stimulation parameters for each participant will remain constant, and the treatment will begin between 8:00 and 10:00 AM each day.
Study: NCT06290869

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone-based Tobacco Treatment, Nicotine Replacement, and Stepped Care Intervention
Description: In the MedStar Health System (MHS) arm, we offer 5 phone sessions with a tobacco treatment specialist (TTS) during the first 3 months of treatment plus combination nicotine replacement (patches and lozenges). For those who have not quit at 3 months, 50% will be randomly assigned to stepped care (3 phone sessions with RN/NP + prescription medications as needed) vs. the continued TTS + NRT intervention. Those who have quit at 3 months will be offered 3 relapse prevention phone sessions with the TTS. Thus, all are offered 8 sessions. The TTS will use motivational interviewing to address ambivalence about quitting, education about the risks of continued smoking, encouragement to use and adhere to NRT, and the impact of the screening result (the teachable moment) by framing it as a potential motivator or opportunity to reduce future health risks and to maximize quality of life.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: E-Referral to the Tobacco Quitline
Description: In the Quitline E-Referral arm, an e-referral will be generated from the EHR by our staff, will be signed by the LCS ordering provider and sent to the quitline through the closed-looped quitline's success.58-61,123 The quitline is an important comparator, given that it is an evidence-based and low-cost intervention already employed by many LCS sites system and the standard quitline protocol will then occur: 5 proactive contact attempts, up to 5 sessions, and up to 8 weeks of free NRT (depending on supplies). Quitline counselors are highly trained to conduct cessation treatment and extensive research has validated the quitline's success. The quitline is an important comparator, given that it is an evidence-based and low-cost intervention already employed by many LCS sites.
Study: NCT06539806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan 50mg Tab
Description: The efficacy of losartan on response rate in both metastatic and locally advanced pancreatic cancer patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan 50mg Tab
Description: The efficacy of losartan on response rate in both metastatic and locally advanced pancreatic cancer patients
Study: NCT06286410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bespoke glasses prescription worn during amblyopia treatment.
Description: The investigators aim to use the information they gather about a participant's accommodation response to be used in a bespoke glasses prescription that will be worn during amblyopia treatment. This is to try and improve vision in those with residual amblyopia following standard amblyopia treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bespoke glasses prescription worn during amblyopia treatment.
Description: The investigators aim to use the information they gather about a participant's accommodation response to be used in a bespoke glasses prescription that will be worn during amblyopia treatment. This is to try and improve vision in those with residual amblyopia following standard amblyopia treatment.
Study: NCT06635733

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Paper-based ISP (Control Group)
Description: Participants in the control group will also receive In-Person Skills Practice (ISP) sessions facilitated by clinical champions, but without the use of the digital platform. The ISP sessions will be tracked and scheduled using paper-based assessments. Feedback will be provided verbally or manually, and progress will be documented using paper forms. Both groups will receive the same PACE adaptive learning modules, but the method of ISP implementation differs between the groups.
Study: NCT04972500

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutricia Pre-op, 400 milliliters, per os
Description: After 10 hours of fasting participants will receive per os 400 milliliters of Nutricia Pre-op
Study: NCT05166018

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SuMO Patient
Description: The current study is interventional insofar as the patient is collecting all of his socio-medical information. The analysis of the data provided by the patient makes it possible to establish a long-term prognosis for the patient but does not in itself constitute a parallel medical approach.~SUMO allows the surgeon to transmit post-operative advice developed by the surgeons themselves.
Study: NCT05200299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6 OR CapeOx
Description: mFOLFOX6(oxaliplatin 85 mg/m2, folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-48 hour continuous infusion on day 1)~CapeOx(Oxaliplatin 130 mg/m2 intravenous infusion on day 1,Capecitabine 1000 mg/m2 twice daily PO for 14 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 OR CapeOx
Description: mFOLFOX6(oxaliplatin 85 mg/m2, folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-48 hour continuous infusion on day 1)~CapeOx(Oxaliplatin 130 mg/m2 intravenous infusion on day 1,Capecitabine 1000 mg/m2 twice daily PO for 14 days)
Study: NCT06040138

Intervention type: DIAGNOSTIC_TEST
Intervention: End expiratory occlusion maneuver
Description: An end expiratory occlusion maneuver will be performed during pressure support ventilation in patients with prolonged weaning.
Study: NCT05861323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comfort Measures Only Time out (CMOT)
Description: This is a brief intensive care unit team (nurse, physician, advanced practice provider, respiratory therapist) intervention to improve communication and care of patients at end of life in the intensive care unit setting.
Study: NCT05057078

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness-based stress reduction program
Description: groups of 10 people will be formed among the patients included in the mindfulness program group. A mindfulness-based stress reduction program will be done once a week for eight weeks and will take approximately 60-120 minutes. A plan will be made with the patients for the day and time of the session. During this process, no application will be made to the control group. Meetings will be held as an online session via Zoom Video Communications.
Study: NCT06599684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-102
Description: 0.7% Ophthalmic Solution
Study: NCT05186493

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot-assisted total pelvic exenteration
Description: Patients with locally advanced pelvic cancer that require pelvic exenteration considered eligble, are operated minimmally invasive robot-assisted
Study: NCT06650137

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: diaphragmatic ultrasound
Description: The examination is performed with a phased array probe, also known as a cardiac probe. The technique used will be that described and validated in anterior studies: the patient is in the Fowler position: half-seated, at an angle of around 45 degrees. The patient is ventilating spontaneously, and no participation is required. The probe is positioned in the sub-costal region between the mid-clavicular and anterior axillary line on the right, and between the anterior and middle axillary line in the sub- or intercostal region on the left. The liver is used as an acoustic window for the right hemi-diaphragm. The probe is oriented medially, cranially and dorsally.~The operator switches to time-motion (TM) mode when an angle of over 70° is achieved between the upper part of the diaphragm and the analysis axis in the most cephalic part of the diaphragm. The image is frozen when 6 respiratory cycles have been measured.
Study: NCT05756868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted feeding
Description: In the time-restricted nutrition intervention, the first meal is scheduled at 10:00 and the last meal at 18:00 (ad libitum). Eating for 8 hours and fasting for 16 hours are targeted.
Study: NCT04906473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KY100001
Description: KY100001; Tablet; Oral route; Dose escalation and dose extension
Study: NCT05744531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-based Parenting Education based on the information -Motivation-Behavioral Skills (IMB) Model
Description: Internet-based Parenting Education based on the information -Motivation-Behavioral Skills (IMB) Model
Study: NCT05643703

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suture method
Description: One-layered Suture: Single layer intermittent suture; Two-layered Suture:Single layer intermittent suture plus U type reinforcement stitching

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suture method
Description: One-layered Suture: Single layer intermittent suture; Two-layered Suture:Single layer intermittent suture plus U type reinforcement stitching
Study: NCT06209424

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Habitual Activity
Description: Participants will maintain habitual levels of physical activity (inclusive of structured physical activity).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Habitual Activity
Description: Participants will maintain habitual levels of physical activity (inclusive of structured physical activity).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Step-Reduction
Description: Participants will be required to reduce their daily step-counts to \<2,000 steps/day. Further, they will be required to refrain from structured physical activity.